TrivarX Limited (AU:TRI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
TrivarX Limited has reported promising results from its Phase 2 SAMDE study, showing its AI-driven algorithm, MEB-001, has the potential to significantly improve depression screening. With an 87% sensitivity rate, these findings bolster TrivarX’s ongoing efforts to engage with the FDA for a pivotal trial, a crucial step towards obtaining regulatory approval. The company also enhanced its leadership team with new appointments to support its strategic objectives.
For further insights into AU:TRI stock, check out TipRanks’ Stock Analysis page.
